Skip to main content
. 2016 Mar 21;7(17):23395–23415. doi: 10.18632/oncotarget.8246

Figure 4. BV6 activates the alternate but not the canonical NF-κB.

Figure 4

A. The indicated human sarcoma cells were treated with BV6 (5 μM) for the indicated time. Cells were then analyzed by Western blotting analysis for p100/p52, pIκBα, and IκBα. B. The indicated human colon carcinoma cells were treated with BV6 (5 μM) for the indicated time and then analyzed for p100/p52, pIκBα, and IκBα as in A. C. The indicated human sarcoma cells were treated with BV6 (5μM, 1 and 2h), TNFα (100 U/ml, 1h), or both as indicated. Nuclear extracts were prepared from the tumor cells and analyzed for canonical NF-κB activity using EMSA with NF-κB consensus sequence-containing DNA probes (Santa Cruz Biotech). Anti-p65 and anti-p50 antibodies were used to identify the canonical NF-κB-DNA complexes. D. SW620 cells were treated with BV6 (5 μM, for 0.5, 1, and 2h) and TNFα (1 h) and analyzed for NF-κB activation as in C.